OAM
CRDF icon

Oxford Asset Management’s Cardiff Oncology CRDF Stock Holding History

Oxford Asset Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,466
Closed -$14K – 455
2019
Q4 		$14K Buy
+11,466
New +$16.3K ﹤0.01% 1700
2016
Q1 		– Sell
-213
Closed -$84K – 817
2015
Q4 		$84K Buy
+213
New +$83.4K ﹤0.01% 845

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Oxford Asset Management's CRDF Position: Q1 2020 in Review

Oxford Asset Management sold out of Cardiff Oncology (CRDF) in Q1 2020, closing a stake of 11,466 shares — an estimated $14K sold.

Oxford Asset Management first reported a position in CRDF in Q4 2015 and held it in 2 quarters. The position peaked at $84K in Q4 2015. 18 funds tracked by Wall St. Rank hold CRDF as of Q1 2020.

  • Oxford Asset Management reported no remaining Cardiff Oncology position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 11,466 Cardiff Oncology shares in Q1 2020, an estimated $14K.
  • Oxford Asset Management first reported a position in Cardiff Oncology in Q4 2015 and held it in 2 quarters.
  • Oxford Asset Management's Cardiff Oncology position peaked at $84K in Q4 2015.
  • 18 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.